Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

There are encouraging signs from Recce Pharmaceuticals' (ASX:RCE) Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections). The trial, is nearing completion, but the results to date have led to a Non-Data Safety Monitoring Board reviewing the trial unanimously recommending it continue. Not only have there been no serious adverse events, but all…

ByNick SundichNovember 6, 2024

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Imugene (ASX:IMU) is still valued at over $400m, in spite of being valued at over $2bn back in 2021 and having had a rollercoaster 12 months. Imugene (ASX:IMU) share price chart, log scale (Source: TradingView) Even though it has assets that have passed Phase 2 trials, it has never gotten to Phase 3. Yet it has $93.1m…

ByNick SundichOctober 22, 2024

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons why. For many companies, the golden market has been the USA, given its population and stringent regulator the Food and Drug Administration (FDA). If a company can commercialise a drug in the USA, it can succeed…

ByNick SundichOctober 15, 2024

Want to participate in the ASX Schools Sharemarket Game? Here are Some Top Strategies for Success!

The ASX Schools Sharemarket Game is on again! And it is a great way for school students to be introduced to the strategic functioning of the share markets. But just because you're not using actual money, it doesn't mean you should take it seriously. This blog will identify the best practices to assist you in…

ByUjjwal MaheshwariOctober 1, 2024

Here Are The Top 5 Websites for Stock Market News & Analysis in Australia

For Australian investors and traders, staying informed about stock market news is essential for making smart decisions. With a range of websites now providing real-time data, expert analysis, and market insights, investors have the tools to navigate the ever-changing world of stocks. This article highlights five of the most reliable websites offering stock market news…

ByUjjwal MaheshwariSeptember 25, 2024

Here are 4 economic indicators that impact stocks and investors must pay attention to

There are several economic indicators that impact stocks, both on the ASX and internationally. Whenever data is released, it can swing market indices in a particular direction, sometimes the opposite direction to where it had been heading earlier in the day. This is not only if the data changes from one period to another, but…

ByNick SundichAugust 19, 2024

As lower interest rates loom, here are 6 ASX stocks that will benefit from forthcoming rate cuts

Here 6 ASX stocks that will benefit from lower interest rates! AGL Energy (ASX:AGL) You might think AGL is on this list because people will have an easier time paying their electricity bills. Not quite for two reasons: First, Blind Freddy could tell you that, and Second, people are still paying their bills. We were…

ByNick SundichAugust 14, 2024

Here’s why investors fear a US recession, and whether the fears are justified

Investors fear a US recession - there's no denying it and there's no other explanation for the market correction in the last week. But are these fears justified? Why investors fear a US recession Because there are data points that are showing markets could be headed that way. There was a very fine tightrope central banks…

ByNick SundichAugust 6, 2024

Is CSL (ASX:CSL) now facing a more difficult FY24 than investors first thought?

After a decade of nothing but good news for investors in CSL (ASX:CSL), shares fell by ~25% between June and October, a decline sparked by profit downgrade and consequential fears that the company's run as the poster child for the ASX biotech sector coming to an end? First published June 21, 2023; last updated December 4,…

ByNick SundichJune 21, 2023

Why did biotech shares underperform in 2022 and will they rebound with a vengence in 2023?

In the past year, biotech shares have performed poorly. Why has this been the case and will things be better in 2023? SIGN UP FOR THE STOCKS DOWN UNDER NEWSLETTER NOW! 1. Investor distaste for high risk assets For one, investors have been put off by the high risk associated with investing in biotech shares as…

ByNick SundichFebruary 24, 2023

the Kick-ass Multipurpose WordPress Theme

Life Sciences

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Here Are The Top 5 Websites for Stock Market News & Analysis in Australia

Here are 4 economic indicators that impact stocks and investors must pay attention to

As lower interest rates loom, here are 6 ASX stocks that will benefit from forthcoming rate cuts

Here’s why investors fear a US recession, and whether the fears are justified

Is CSL (ASX:CSL) now facing a more difficult FY24 than investors first thought?

Why did biotech shares underperform in 2022 and will they rebound with a vengence in 2023?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Life Sciences

Stocks in Spotlight

Add Your Heading Text Here